Continued Growth of Personal Genomics with a PerkinElmer/Helix Collaboration

Genomic testing is beginning to explode in the consumer marketplace. The phenomenon started with DNA analysis for those interested in their family lineage and is now proceeding to diagnostics such as the determination of selected variants ofBRCA1/BRCA 2. This is only one of the analytes included in the genetic risk report of 23andMe (see:Do You Speak BRCA). Now comes the news that PerkinElmer, a well established IVD company, is collaborating withHelix to offer personal genomic testing to consumers (see:PerkinElmer Collaborates With Helix To Drive Innovation In Exome-Based Personal Genomics). Below is an excerpt from the article announcing this news:PerkinElmer has announced a collaboration with Helix to develop and commercialize exome sequencing-based tests that will empower consumers to make proactive health management decisions. Tests developed as part of this collaboration will be available to customers of Helix ’s expanding online marketplace for DNA-powered products, which were utilized in Helix’s collaboration withIllumina Accelerator last fall. The initial targeted product offering will return results for 59 genes that the American College of Medical Genetics and Genomics (ACMG) identifies as highly penetrant genetic conditions with established interventions aimed at significantly reducing morbidity and mortality.All DNA sequencing data for these products will be generated utilizing Helix ’s proprietary Exome+ assay in its CLIA- and CAP-certified next...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: Clinical Lab Industry News Clinical Lab Testing Genomic Testing Healthcare Information Technology Healthcare Innovations Lab Industry Trends Lab Processes and Procedures Reference Laboratories Source Type: blogs